The 110,000 ft2 site, which is set to be operational by the second half of 2021, will feature new technology including 2000-L scale bioreactors and additional fill-finish capabilities.
Vibalogics, a Germany-based contract development and manufacturing organization (CDMO), announced on Nov. 16, 2020 that it has begun its three-year, $150 million investment into a late-phase clinical and commercial virotherapy manufacturing facility near Boston, MA, thus establishing its presence in the United States.
The 110,000 ft2 site, which is set to be operational by the second half of 2021, will feature new technology including 2000-L scale bioreactors and additional fill/finish capabilities, a company press release said.
“We are very excited about our choice of facility, as it meets both our current and future needs, giving us the ability to expand further to meet growing customer demand,” said Tom Hochuli, Vibalogics’ CEO, in the press release. “The site will provide a complete suite of virotherapy services to support drug developers and their most revolutionary products. The addition of a late stage clinical and commercial facility means we can easily tech transfer our customers’ products from our early phase manufacturing facility in Germany to the US, resulting in a complete end-to-end service from pre-clinical to commercial supply.”
Source: Vibalogics
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.